Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
Accession Number
DB10584
Description
Not Available
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Diphtheria toxoid
  • Diphtheria toxoid adsorbed

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Diphtheria ToxoidLiquidSubcutaneousAventis Pasteur Limited1925-12-312001-07-19Canada
Diphtheria Toxoid for Reaction Test 0.2lf/mlLiquidIntradermalAventis Pasteur Limited1955-01-012000-04-06Canada
Diphtheria Toxoid for Schick Control 0.2lf/mlLiquidIntradermalConnaught Laboratories Ltd.1925-12-311996-09-10Canada
Diphtheria Toxoid Immunization Of ReactorsLiquidSubcutaneousAventis Pasteur Limited1933-12-312001-07-19Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Adacel TDaPCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2005-06-10Not applicableUs
Adacel TDaP TDaPCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularRemedy Repack2015-11-142016-03-29Us
BoostrixCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2009-07-24Not applicableUs
BoostrixCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL)SuspensionIntramuscularA-S Medication Solutions2009-07-24Not applicableUs
BoostrixCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2.5 [iU]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (8 ug/0.5mL) + Bordetella pertussis pertactin antigen (formaldehyde inactivated) (2.5 ug/0.5mL) + Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) (8 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [iU]/0.5mL)SuspensionIntramuscularA-S Medication Solutions2009-07-24Not applicableUs
CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), CORYNEBACTERIUM DIPHTHERIAE TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, and BORDETELLA PERTUSSIS FIMBRIAE 2/3 ANTIGENCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (2.5 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularA-S Medication Solutions2005-06-10Not applicableUs
D2t5Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 lf) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 lf)SuspensionIntramuscularID Biomedical Corporation of Quebec1991-12-312005-08-03Canada
DaptacelCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (5 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (10 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Inc.2002-05-14Not applicableUs
DecavacCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (2 [Lf]/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)SuspensionIntramuscularSanofi Pasteur Limited2004-03-242016-05-19Us
Diphtheria and Tetanus Toxoids AdsorbedCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (6.7 [Lf]/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL)Injection, suspensionIntramuscularSanofi Pasteur Limited1984-09-182013-03-18Us

Categories

ATC Codes
J07AF01 — Diphtheria toxoid
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
IRH51QN26H
CAS number
308079-75-6

References

General References
Not Available
RxNav
235600
AHFS Codes
  • 36:28.00 — Diphtheria
  • 80:08.00 — Toxoids

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingBasic SciencePrevention of Infections With Bordetella Pertussis1
4Active Not RecruitingPreventionDiphtheria / Pertussis / Tetanus1
4Active Not RecruitingPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis1
4Active Not RecruitingPreventionPertussis1
4CompletedNot AvailableDisseminated Sclerosis1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-acellular Pertussis Vaccines / Tetanus1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionAcellular Pertussis / Diphtheria / Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines / Poliomyelitis / Tetanus1
4CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Haemophilus Influenzae Type b (Hib) / Pertussis / Poliomyelitis / Tetanus / Viral Hepatitis B1
4CompletedPreventionAcellular Pertussis / Diphtheria / Haemophilus Influenzae Type B / Poliomyelitis / Tetanus / Viral Hepatitis B1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntramuscular
Injection, suspensionIntramuscular
LiquidIntramuscular
LiquidSubcutaneous
LiquidIntradermal
InjectionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:04 / Updated on August 05, 2020 23:35

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates